Status: current, Sufficiently defined by necessary conditions definition status. Date: 30-Jun 2022. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5073035019 | Rotigotine 41.667 microgram/hour prolonged-release transdermal patch | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| 5073036018 | Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Is a | Product containing only rotigotine in transdermal dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has manufactured dose form | Prolonged-release transdermal patch | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Plays role | Antiparkinson therapeutic role | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has precise active ingredient | Rotigotine | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has basis of strength substance | Rotigotine | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has concentration strength numerator unit | microgram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) | Has concentration strength denominator unit | hour | true | Inferred relationship | Existential restriction modifier | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR